FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2958415056> ?p ?o ?g. }

• W2958415056 endingPage "1283" @default.
• W2958415056 startingPage "1283" @default.
• W2958415056 abstract "Patients with oligometastatic non-small cell lung cancer (NSCLC) may benefit from locally ablative therapy (LAT) such as surgery or stereotactic radiotherapy. Prior studies were conducted before the advent of immunotherapy, and a strong biological rationale for the use of immunotherapy exists in a minimal residual disease state.To evaluate whether the addition of pembrolizumab after LAT improves outcomes for patients with oligometastatic NSCLC.This single-arm phase 2 trial of pembrolizumab therapy was performed from February 1, 2015, through September 30, 2017, at an academic referral cancer center. The 51 eligible patients enrolled had oligometastatic NSCLC (≤4 metastatic sites) and had completed LAT to all known sites of disease. Data were analyzed from February 1, 2015, to August 23, 2018.Within 4 to 12 weeks of completing LAT, patients began intravenous pembrolizumab therapy, 200 mg every 21 days, for 8 cycles, with provision to continue to 16 cycles in the absence of progressive disease or untoward toxic effects.The 2 primary efficacy end points were progression-free survival (PFS) from the start of LAT (PFS-L), which preceded enrollment in the trial, and PFS from the start of pembrolizumab therapy (PFS-P). The study was powered for comparison with historical data on the first efficacy end point. Secondary outcomes included overall survival, safety, and quality of life as measured by the Functional Assessment of Cancer Therapy-Lung instrument.Of 51 patients enrolled, 45 (24 men [53%]; median age, 64 years [range, 46-82 years]) received pembrolizumab. At the time of analysis, 24 patients had progressive disease or had died. Median PFS-L was 19.1 months (95% CI, 9.4-28.7 months), significantly greater than the historical median of 6.6 months (P = .005). Median PFS-P was 18.7 months (95% CI, 10.1-27.1 months). Eleven patients died. Overall mean (SE) survival rate at 12 months was 90.9% (4.3%); at 24 months, 77.5% (6.7%). Neither programmed death ligand 1 expression nor CD8 T-cell tumor infiltration was associated with PFS-L. Pembrolizumab after LAT yielded no new safety signals and no reduction in quality of life.Pembrolizumab after LAT for oligometastatic NSCLC appears to improve PFS with no reduction in quality of life.ClinicalTrials.gov identifier: NCT02316002." @default.
• W2958415056 created "2019-07-23" @default.
• W2958415056 creator A5003297339 @default.
• W2958415056 creator A5005833178 @default.
• W2958415056 creator A5015582820 @default.
• W2958415056 creator A5026118713 @default.
• W2958415056 creator A5030099528 @default.
• W2958415056 creator A5052264374 @default.
• W2958415056 creator A5056098854 @default.
• W2958415056 creator A5062034160 @default.
• W2958415056 creator A5072325015 @default.
• W2958415056 creator A5076698606 @default.
• W2958415056 creator A5077341941 @default.
• W2958415056 creator A5087603353 @default.
• W2958415056 creator A5088542967 @default.
• W2958415056 creator A5090256464 @default.
• W2958415056 date "2019-09-01" @default.
• W2958415056 modified "2023-10-13" @default.
• W2958415056 title "Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer" @default.
• W2958415056 cites W1969531640 @default.
• W2958415056 cites W1981876938 @default.
• W2958415056 cites W2014725195 @default.
• W2958415056 cites W2033052459 @default.
• W2958415056 cites W2052354574 @default.
• W2958415056 cites W2059812828 @default.
• W2958415056 cites W2099725888 @default.
• W2958415056 cites W2104504726 @default.
• W2958415056 cites W2149564448 @default.
• W2958415056 cites W2198093519 @default.
• W2958415056 cites W2511769828 @default.
• W2958415056 cites W2527905628 @default.
• W2958415056 cites W2536769127 @default.
• W2958415056 cites W2753065806 @default.
• W2958415056 cites W2761351587 @default.
• W2958415056 cites W2787553571 @default.
• W2958415056 cites W2794625598 @default.
• W2958415056 cites W2796582438 @default.
• W2958415056 cites W2892640821 @default.
• W2958415056 cites W2893824814 @default.
• W2958415056 cites W2901105904 @default.
• W2958415056 cites W2925446385 @default.
• W2958415056 cites W4231096603 @default.
• W2958415056 cites W4243885264 @default.
• W2958415056 cites W4256154916 @default.
• W2958415056 doi "https://doi.org/10.1001/jamaoncol.2019.1449" @default.
• W2958415056 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6624820" @default.
• W2958415056 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31294762" @default.
• W2958415056 hasPublicationYear "2019" @default.
• W2958415056 type Work @default.
• W2958415056 sameAs 2958415056 @default.
• W2958415056 citedByCount "197" @default.
• W2958415056 countsByYear W29584150562019 @default.
• W2958415056 countsByYear W29584150562020 @default.
• W2958415056 countsByYear W29584150562021 @default.
• W2958415056 countsByYear W29584150562022 @default.
• W2958415056 countsByYear W29584150562023 @default.
• W2958415056 crossrefType "journal-article" @default.
• W2958415056 hasAuthorship W2958415056A5003297339 @default.
• W2958415056 hasAuthorship W2958415056A5005833178 @default.
• W2958415056 hasAuthorship W2958415056A5015582820 @default.
• W2958415056 hasAuthorship W2958415056A5026118713 @default.
• W2958415056 hasAuthorship W2958415056A5030099528 @default.
• W2958415056 hasAuthorship W2958415056A5052264374 @default.
• W2958415056 hasAuthorship W2958415056A5056098854 @default.
• W2958415056 hasAuthorship W2958415056A5062034160 @default.
• W2958415056 hasAuthorship W2958415056A5072325015 @default.
• W2958415056 hasAuthorship W2958415056A5076698606 @default.
• W2958415056 hasAuthorship W2958415056A5077341941 @default.
• W2958415056 hasAuthorship W2958415056A5087603353 @default.
• W2958415056 hasAuthorship W2958415056A5088542967 @default.
• W2958415056 hasAuthorship W2958415056A5090256464 @default.
• W2958415056 hasBestOaLocation W29584150561 @default.
• W2958415056 hasConcept C121608353 @default.
• W2958415056 hasConcept C126322002 @default.
• W2958415056 hasConcept C141071460 @default.
• W2958415056 hasConcept C143998085 @default.
• W2958415056 hasConcept C203092338 @default.
• W2958415056 hasConcept C2776256026 @default.
• W2958415056 hasConcept C2777701055 @default.
• W2958415056 hasConcept C2780057760 @default.
• W2958415056 hasConcept C509974204 @default.
• W2958415056 hasConcept C535046627 @default.
• W2958415056 hasConcept C71924100 @default.
• W2958415056 hasConceptScore W2958415056C121608353 @default.
• W2958415056 hasConceptScore W2958415056C126322002 @default.
• W2958415056 hasConceptScore W2958415056C141071460 @default.
• W2958415056 hasConceptScore W2958415056C143998085 @default.
• W2958415056 hasConceptScore W2958415056C203092338 @default.
• W2958415056 hasConceptScore W2958415056C2776256026 @default.
• W2958415056 hasConceptScore W2958415056C2777701055 @default.
• W2958415056 hasConceptScore W2958415056C2780057760 @default.
• W2958415056 hasConceptScore W2958415056C509974204 @default.
• W2958415056 hasConceptScore W2958415056C535046627 @default.
• W2958415056 hasConceptScore W2958415056C71924100 @default.
• W2958415056 hasIssue "9" @default.
• W2958415056 hasLocation W29584150561 @default.
• W2958415056 hasLocation W29584150562 @default.
• W2958415056 hasLocation W29584150563 @default.

• next